Cinemark Holdings heads into October with shorts trimming exposure and options positioning shifting away from its most defensive extreme, even as the stock trades just below consensus targets.
Short interest has pulled back meaningfully over the past month. At 6.7% of the free float, the short position is down roughly 5% over the past 30 days and down a further 3.4% on the week, with the most recent FINRA settlement data putting shares short at around 7.3 million. That withdrawal is happening against a backdrop of very loose borrow conditions: availability runs at more than 13 times the existing short interest, one of the highest readings of the past year, and the cost to borrow is just 0.46%, though that figure is up 44% over the past month from a lower base. There is no squeeze pressure here. The borrow market is wide open, and the retreat in short interest looks more like conviction fading than shorts being forced out. Borrowing costs in the mid-August period, when availability briefly tightened to around a third of its current level and utilisation hit 23%, have since fully normalised.
Options positioning tells a complementary story. The put/call ratio has dropped to 1.15, nearly two standard deviations below its 20-day average of 1.21. That is close to the 52-week low for this ratio. Through September, the PCR had been running consistently above 1.20, reflecting persistent demand for downside protection. The shift in the final week of the month is notable: call interest is picking up relative to puts at a time when the stock has gained 6.6% over the week to $38.24. Whether that reflects short-covering-driven momentum or fresh bullish positioning, the defensive overhang in the options market is clearly easing.
The Street is broadly constructive but not uniformly so. A Morgan Stanley analyst trimmed the price target to $40 from $42 last week while holding an Equal-Weight rating, a modest step back that keeps the stock near consensus. Macquarie raised its target to $44 in early September, maintaining Outperform. JP Morgan downgraded to Neutral in mid-August, cutting the target to $39, which at the current price of $38.24 implies minimal upside from that desk. The mean target across the analyst base sits at $39.82, barely above the current price, though buyers at Macquarie, Wedbush, and Benchmark all carry targets in the $40 to $44 range. The valuation picture is undemanding: EV/EBITDA is running at roughly 9x, down fractionally over the past month, and the PE stands at about 14.8x. Factor scores are mixed. Forward EPS estimate revisions rank in the 98th percentile on a 12-month basis, a standout number, while the short score rank at the 29th percentile confirms that this is not a name where short pressure is particularly elevated relative to the broader universe.
Ownership is a point of interest. BlackRock holds 14.6% of shares, the largest single institutional position, and added around 924,000 shares in the most recent reporting period. Orbis Investment Management, with 13.1%, has been steadily building since it held 9.8% in early 2025. Lavaca Capital reported a position of 8.8% as of June, having added more than 8 million shares in the period, the largest single-quarter addition among the top holders. Wellington trimmed from 8.3% to 6.7% in its most recent 13G/A filing, the only notable reduction among the larger holders. There are no 13D activists on the register. The insider register shows a series of planned disposals under 10b5-1 programmes: the CEO sold around $5.3 million of stock in late August and the CFO sold $1.4 million around the same time, with further scheduled sales from other executives in September. All are flagged as pre-arranged plan sales, so they carry limited informational weight as a read on management conviction.
Earnings are due on 6 November, giving the stock 37 days before the next catalyst. The most recent print, in late July, produced a one-day gain of nearly 5% and a five-day gain of 8.8%. The August result was essentially flat on the day. Attention metrics from Wikipedia and ORTEX page views are running below the prior 90-day average, suggesting the stock is not generating unusual retail interest at this point in the cycle. The key question heading into November is whether the strong forward EPS revision trend, the highest-ranked factor in the snapshot, translates into another positive surprise, or whether the tightening in analyst targets signals that expectations have already been largely reset.
See the live data behind this article on ORTEX.
Open CNK on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
